HeimSTIM • NASDAQ
add
Neuronetics Inc
Við síðustu lokun
0,95 $
Dagbil
0,92 $ - 0,95 $
Árabil
0,52 $ - 5,07 $
Markaðsvirði
26,57 m. USD
Meðalmagn
610,88 þ.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
NASDAQ
Viðskiptafréttir
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 18,53 m. | 3,61% |
Rekstrarkostnaður | 21,73 m. | 5,30% |
Nettótekjur | -13,34 m. | -42,06% |
Hagnaðarhlutfall | -72,00 | -37,12% |
Hagnaður á hvern hlut | -0,44 | -33,33% |
EBITDA | -7,17 m. | 13,99% |
Virkt skatthlutfall | — | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 20,87 m. | -41,79% |
Heildareignir | 74,12 m. | -20,29% |
Heildarskuldir | 64,74 m. | 17,60% |
Eigið fé alls | 9,38 m. | — |
Útistandandi hlutabréf | 30,35 m. | — |
Eiginfjárgengi | 3,08 | — |
Arðsemi eigna | -22,61% | — |
Ávöxtun eigin fjár | -27,58% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | -13,34 m. | -42,06% |
Handbært fé frá rekstri | -5,42 m. | 46,49% |
Reiðufé frá fjárfestingum | 14,00 þ. | -78,79% |
Reiðufé frá fjármögnun | -16,37 m. | — |
Breyting á handbæru fé | -21,78 m. | -116,49% |
Frjálst peningaflæði | -2,85 m. | 62,41% |
Um
Neuronetics is a Malvern, PA based, publicly traded company incorporated in Delaware in April 2003, that develops non-invasive treatments for psychiatric disorders that have shown resistance or lack of improvement using traditional medicine. The treatments are based upon neuromodulation technology.
Neuronetics became the "first and only Food and Drug Administration approval for the clinical treatment of a specific form of medication-refractory depression using a TMS Therapy device."
They manufacture a transcranial magnetic stimulation device, NeuroStar. The NeuroStar TMS therapy is delivered via a precisely positioned magnetic coil against the patient's head. Wikipedia
Stofnsett
2003
Höfuðstöðvar
Vefsvæði
Starfsfólk
201
